No Data
No Data
UroGen Pharma Is Maintained at Outperform by Oppenheimer
UroGen Pharma Is Maintained at Outperform by Oppenheimer
Oppenheimer: UroGen Pharma (URGN.US) rating was maintained, and the target price was adjusted from superior to superior to market, and the target price was adjusted from $34.00 to $32.00.
Oppenheimer: UroGen Pharma (URGN.US) rating was maintained, and the target price was adjusted from superior to superior to market, and the target price was adjusted from $34.00 to $32.00.
Oppenheimer Maintains Outperform on UroGen Pharma, Lowers Price Target to $32
Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperform and lowers the price target from $34 to $32.
Earnings Call Summary | UroGen Pharma Ltd(URGN.US) Q1 2024 Earnings Conference
The following is a summary of the UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript:Financial Performance:UroGen Pharma reported Q1 2024 revenue of $18.8 million, showing a 10% increase than
UroGen Pharma Ltd (URGN) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...
UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript
UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript
No Data